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Abstract
Introduction: We compared the odds of vitamin D deficiency in three chronic diseases: systemic lupus
erythematosus (SLE), rheumatoid arthritis (RA), and type 2 diabetes (T2DM), adjusting for medications,
demographics, and laboratory parameters, common to all three diseases. We also designed multivariate models to
determine whether different factors are associated with vitamin D deficiency in different racial/ethnic groups.
Methods: We identified all patients with non-overlapping diagnoses of SLE, RA, and T2DM, with 25-hydroxyvitamin
D (25OHD) levels measured between 2000 and 2009. Vitamin D deficiency was defined as 25OHD levels <20 ng/
ml, based on previously established definitions. Race/ethnicity was analyzed as African-American non-Hispanic
(African-American), Hispanic non-African-American (Hispanic), and Other based on self report.
Results: We included 3,914 patients in the final analysis: 123 SLE, 100 RA, and 3,691 T2DM. Among African-
Americans the frequency of vitamin D deficiency was 59% in SLE, 47% in RA, and 67% in T2DM. Among Hispanics
the frequency of vitamin D deficiency was 67% in SLE, 50% in RA, and 59% in T2DM. Compared with the SLE
group, the adjusted odds ratio of vitamin D deficiency was 1.1, 95% CI (0.62, 2.1) in the RA group, and 2.0, 95% CI
(1.3, 3.1) in the T2DM group. In the multivariate analysis, older age, higher serum calcium and bisphosphonate
therapy were associated with a lower odds of vitamin D deficiency in all three racial/ethnic groups: 1,330 African-
American, 1,257 Hispanic, and 1,100 Other. T2DM, serum creatinine, and vitamin D supplementation were
associated with vitamin D deficiency in some, but not all, racial/ethnic groups.
Conclusions: Vitamin D deficiency is highly prevalent in our patients with SLE, RA, and T2DM. While the odds of
vitamin D deficiency are similar in RA and SLE patients in a multivariate analysis, T2DM patients have much higher
odds of being vitamin D deficient. Different demographic and laboratory factors may be associated with vitamin D
deficiency within different racial/ethnic groups. Therefore, disease-specific and race/ethnicity-specific definitions of
vitamin D deficiency need to be established in future studies in order to define goals of vitamin D replacement in
patients with autoimmune and non-autoimmune chronic diseases.
Introduction
Vitamin D deficiency and insufficiency, defined as 25-
hydroxyvitamin D (25OHD) levels below 20 ng/ml and
30 ng/ml, respectively [1], are very common in patients
with autoimmune and non-autoimmune chronic dis-
eases, including systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), and type 2 diabetes (T2DM)
[2,3].
While several studies explored factors associated with
vitamin D deficiency in SLE [4-9], only a few studies
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have compared vitamin D status in SLE and other auto-
immune and non-autoimmune chronic diseases, with
mixed results. Two cross-sectional studies demonstrated
that SLE patients had significantly lower vitamin D
levels compared with rheumatoid arthritis and osteoar-
thritis patients [10,11]. However, these studies included
relatively small numbers of patients, and used bivariate
comparisons without adjusting for medications, demo-
graphics, and laboratory parameters. In a pilot study
from Canada, when vitamin D status was compared in
25 patients with SLE and a demographically similar
group of 25 fibromyalgia patients, no statistically signifi-
cant differences were found between the two groups,
with half of the patients in both groups being vitamin D
deficient [12].
Furthermore, while it is well established that African-
Americans and Hispanics have lower vitamin D levels in
several diseases as well as in the general population
[8,13-15], only a few studies have evaluated whether dif-
ferent demographic and laboratory factors were asso-
ciated with vitamin D deficiency in different racial/
ethnic groups [16,17]. Patients with autoimmune dis-
eases were not included in these studies. In addition,
recent studies have suggested that vitamin D replace-
ment goals may be different in Caucasians and in Afri-
can-Americans with non-autoimmune diseases. While
calcium and vitamin D supplementation in Caucasians
is associated with a decreased risk of fractures [18],
higher vitamin D levels may be associated with
increased arterial plaque, a measure of cardiovascular
risk, in African-Americans with diabetes [19]. This
important question has not been addressed in SLE or
RA, even though African-Americans and Hispanics are
at a higher risk for vitamin D deficiency, and suffer
more severe manifestations of SLE and RA [20].
Therefore, we designed a study to compare the odds
of vitamin D deficiency in an ethnically diverse retro-
spective cohort with three chronic diseases: SLE, RA,
and T2DM. T2DM was chosen as a non-autoimmune
disease comparison group since as with SLE and RA, it
is a chronic disease with wide range of manifestations, a
variable course, requires multiple medications to con-
trol, and may have multi-system involvement, including
renal, cardiovascular, and metabolic bone disease.
Furthermore, laboratory and epidemiologic studies sug-
gest that vitamin D deficiency may play a role in the
pathogenesis of RA [20,21], SLE [22], and T2DM [23].
Materials and methods
Patients
We identified all patients with ICD9 (International Clas-
sification of Diseases, 9th revision) diagnoses of SLE
(710.0, 695.4), RA (714.0, 714.2) and T2DM (250.*,
excluding ICD9 codes for type 1 diabetes) with at least
one 25-hydroxyvitamin D (25OHD) measurement
occurring between January 2000 and August 2009 at
Montefiore Medical Center (MMC), a large urban ter-
tiary care center in the Bronx, NY, the University Hospi-
tal for the Albert Einstein College of Medicine. Patients
were identified from the Montefiore electronic record
system using Clinical Looking Glass (CLG), a software
application developed at MMC, which allows clinicians
and researchers to identify populations of interest,
laboratory data, medications, and demographics from
the MMC database [24].
Because of the retrospective nature of this study, it
was not necessary to obtain informed consent from the
patients, as no identifying information was stored or
used in the data analysis. This project was approved by
the Institutional Review Board at Albert Einstein College
of Medicine/Montefiore Medical Center.
All SLE and RA diagnoses were reviewed by a rheu-
matologist (A.B.) who was not aware of the vitamin D
status prior to reviewing the charts. It was not feasible
to review all T2DM charts or to document fasting glu-
cose measurement from the electronic database to use
the American Diabetes Association (ADA) definition of
T2DM [25]. Therefore, we only included patients with
T2DM if they had a documented ICD9 diagnosis of type
2 diabetes, and a hemoglobin A1c >7.0% on at least two
occasions. Patients with dual ICD9 diagnoses of SLE,
RA or T2DM, or patients with coexisting ICD9 diag-
noses for other autoimmune diseases were not included
in our analysis.
Race/ethnicity was defined based on self report and
was analyzed as African-American non-Hispanic (Afri-
can-American), Hispanic non-African-American (Hispa-
nic), and Other. Seasons were defined based on the
degree of sun exposure into “light” (April to September)
and “dark” (October to March) seasons. Vitamin D sup-
plementation was analyzed as a yes/no variable. The
most common dose of supplementation was 400-800
IU/day, and did not differ by disease.
Vitamin D measurements
25OHD levels were measured in Montefiore Laboratory
using Diasorin Liaison chemiluminescent assay [26] for
all patients. We used the earliest recorded 25OHD mea-
surement in our data analysis.
Data analysis
Statistical analysis was performed using the STATA 10.0
software package (StataCorp, College Station, Texas,
USA). We used ANOVA (or its non-parametric alterna-
tive, Kruskal-Wallis rank test) and the chi-square test to
evaluate bivariate relationships between continuous and
categorical variables, respectively, in the three disease
groups.
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Logistic regression was performed with 25OHD <20
ng/ml as the main outcome, and disease category (SLE,
RA, T2DM), as the main variable of interest in the over-
all cohort, and within each racial/ethnic group. Variables
were considered in the logistic regression either if they
were shown to be significantly associated with 25OHD
in previous studies, or if they were associated with dis-
ease category (P < 0.2) in the bivariate analysis. Logistic
regression models were used to assess for interactions,
to adjust for confounding, and to test for statistical
assumptions using the Hosmer-Lemeshow goodness-of-
fit statistic.
Results
Based on our chart review, 100 patients with ICD9 diag-
nosis of RA and 123 patients with ICD9 diagnosis of
SLE satisfied the American College of Rheumatology
(ACR) criteria [27,28]. Patients with ICD9 of SLE (n =
43) and RA (n = 105) who did not meet the ACR cri-
teria had heterogeneous diagnoses including fibromyal-
gia, mixed connective tissue disease, and other causes of
inflammatory arthritis. While the median 25OHD levels
were not statistically significantly different between con-
firmed SLE and “SLE by ICD9”, the median 25OHD
levels were statistically significantly different between
confirmed RA and “RA by ICD9”. Therefore, in order to
minimize misclassification bias, only SLE and RA
patients who satisfied the ACR criteria were included in
the final analysis.
The distribution of RA, SLE, and T2DM patients who
had 25OHD measured each year was similar within the
study period. The median (Inter-Quartile Range, IQR)
duration of follow-up, from the defining diagnosis to the
time when 25OHD was measured, was 2.6 (0.6, 6.3) years
in the SLE group, 2.7 (1.0, 7.5) years in the RA group,
and 2.6 (0.8, 5.4) years in the T2DM group (P = 0.11).
Demographic and laboratory data for SLE, RA, and
T2DM groups are provided in Table 1. Seventy-five per-
cent of RA and 86% of SLE and T2DM patients were
vitamin D deficient or insufficient. Compared with RA
and T2DM, SLE patients were significantly younger, and
there were more women in the SLE and RA groups.
There were no statistically significant racial/ethnic dif-
ferences among the three groups. The median (IQR)
25OHD levels were significantly higher in the RA group,
20.9 (16.1, 29.9) ng/ml, compared with the SLE group,
18.0 (11.3, 25.4) ng/ml, and T2DM group, 16.8 (11.1,
24.2) ng/ml (P < 0.0001).
The results of the multivariate analysis are summarized
in Table 2. T2DM patients were twice as likely to be vita-
min D deficient compared with SLE patients (P = 0.003).
However, the odds ratio of vitamin D deficiency in RA
was not statistically or clinically different compared with
SLE (OR 1.1, P = 0.691). Younger age, African-American
race, serum creatinine >1.5 mg/dl, and 25OHD measure-
ment during the “dark” season (October to March) were
associated with vitamin D deficiency in this model.
Bisphosphonate therapy, vitamin D supplementation, and
higher serum calcium were associated with increased
odds of having 25OHD levels ≥ 20 ng/ml. Gender, cal-
cium supplementation and prednisone use were not sta-
tistically significantly associated with vitamin D
deficiency. Furthermore, patients with SLE or RA were
38% less likely to be vitamin D deficient compared with
T2DM patients (95% CI 0.42, 0.91, P = 0.015).
Body mass index (BMI) data from the electronic medi-
cal record were only available for 35% SLE, 48% T2DM,
and 29% RA patients within one year around the time
when 25-OHD was measured. The median (IQR) BMI
was statistically and clinically similar between RA and
T2DM groups: 30.2 kg/m2 (24.9, 36.3), and 30.3 kg/m2
(26.1, 36.1), respectively. SLE patients had lower median
(IQR) BMI, 24.1 kg/m2 (20.2, 30.6), compared with RA
and T2DM, P = 0.001. BMI over 30 kg/m2 was asso-
ciated with 25-OHD levels <20 ng/ml in the bivariate
analysis, consistent with previous reports [7,29]. How-
ever, adding BMI into our model did not change the
main conclusions of the study, and BMI did not appear
to be a confounder.
Among African-Americans, the frequency of severe vita-
min D deficiency (<10 ng/mL) was 24% in SLE, 13% in
RA, and 26% in T2DM. Among Hispanics the frequency
of severe vitamin D deficiency was 14% in SLE, 14% in RA,
and 17% in T2DM. The rates of vitamin D deficiency and
insufficiency varied by disease and by race/ethnicity (Table
3). In addition, there was a statistically significant interac-
tion between disease category and race/ethnicity, suggest-
ing that race/ethnicity was an effect modifier.
Therefore, we created separate logistic regression mod-
els by race/ethnicity, and the results are summarized in
Tables 4, 5, 6. Older age, higher serum calcium, and
bisphosphonate therapy were each associated with the
lower odds of vitamin D deficiency in all three racial/eth-
nic groups. T2DM was associated with the higher odds of
vitamin D deficiency in Others and in African-Ameri-
cans, but not in Hispanics. Serum creatinine >1.5 mg/dl
were associated with the higher odds of vitamin D defi-
ciency in African-Americans and Hispanics, but not in
Others. Vitamin D supplementation was associated with
the lower odds of vitamin D deficiency only in Others.
Discussion
In this study we showed that 25OHD deficiency and fac-
tors associated with it vary in autoimmune and non-
autoimmune chronic diseases and in different racial/eth-
nic groups. Based on our literature review, this issue has
not been previously addressed. In addition, our findings
underscore the importance of using multivariate analysis
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when comparing 25OHD levels in different diseases.
Furthermore, based on the results of our study, we were
able to identify new directions for future studies.
Factors associated with vitamin D deficiency in SLE, RA,
and T2DM
We demonstrated that patients with T2DM have signifi-
cantly higher odds of being vitamin D deficient com-
pared with SLE and RA patients in the multivariate
analysis, while the rates of vitamin D deficiency were
not different between SLE and RA patients. The differ-
ence in 25OHD levels in SLE and RA compared with
T2DM may reflect biases among physicians: 25OHD
was measured in over 30% of all SLE and RA patients in
the database compared with only 14% of T2DM
patients. Moreover, T2DM patients were less likely to
be prescribed calcium, bisphosphonates, or vitamin D
supplementation, despite being significantly older than
SLE patients. This suggests that rheumatologists, who
often are both the specialty and primary care providers
for SLE and RA patients, may be more aggressive at
vitamin D replacement, especially since a large percen-
tage of SLE and RA patients are on prednisone.
Alternatively, there may be disease-specific biologic
mechanisms leading to the differences demonstrated in
our study, such as immunity-related effects of vitamin D
in SLE and RA, and metabolic effects of vitamin D in
T2DM [21,30].
Another important finding of our study was that older
age was associated with the lower odds of vitamin D
deficiency in the overall model and across all three
racial/ethnic groups. In the overall model, for every dec-
ade increase in age, the odds of 25OHD deficiency
decreased by 16% (P < 0.001). While the mean vitamin
D levels did not differ by age in the National Health and
Nutrition Examination Survey (NHANES) 2001 to 2004
[13], an association between older age and higher vita-
min D levels was previously reported in SLE [5]. This
association has not been reported in RA or T2DM.
Table 1 Demographic and laboratory data by disease
SLE RA T2DM P-value
n = 123 n = 100 n = 3691
Age, years Median (IQR) 34.5 (26.7, 47.7) 60.5 (52.6, 66.8) 63.3 (53.7, 71.7) <0.001
Gender (% female) 109 (89) 88 (88) 2,686 (73) <0.001
Race/Ethnicity (%)
African-American 46 (39) 32 (34) 1,252 (36)
Hispanic 39 (33) 42 (45) 1,176 (34) 0.199
Other 34 (29) 20 (21) 1,046 (30)
Unknown 14 (12%) 16 (16%) 217 (6%)
25OHD, ng/ml
Median (IQR) 18.0 (11.3, 25.4) 20.9 (16.1, 29.9) 16.8 (11.1, 24.2) 0.0001
Season (%)
April-September 61 (50) 50 (50) 1,698 (46) 0.47
Serum creatinine >1.5 mg/dl (%) 16 (13) 2(2) 855 (27) <0.001
Serum calcium, mg/dl
Median (IQR) 9.2 (8.9, 9.5) 9.5 (9.1, 9.7) 9.6 (9.2, 10) 0.001
Bisphosphonates use (%) 20 (16) 34 (34) 346 (9) <0.001
Calcium supplementation (%) 60 (49) 59 (59) 864 (23) <0.001
Prednisone use (%) 85 (69) 65 (65) 231 (6) <0.001
Vitamin D supplementation (%) 57 (46) 56 (56) 867 (23) <0.0001
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T2DM, type 2 diabetes mellitus; 25OHD, 25hydroxyvitamin D; IQR, inter-quartile range.
Table 2 Logistic Regression model for 25OHD deficiency
(n = 3,173)
OR (95% CI) P -value
SLE 1.0
RA 1.1 (0.62, 2.1) 0.691
T2DM 2.0 (1.3, 3.1) 0.003
Age (for every decade) 0.83 (0.78, 0.88) <0.001
Male gender 0.95 (0.79, 1.1) 0.58
Race/Ethnicity
African-American 1.0
Hispanic 0.75 (0.63, 0.90) 0.002
Other 0.70 (0.58, 0.84) <0.001
October to March season 1.3 (1.1, 1.5) 0.002
Serum calcium, mg/dl 0.70 (0.63, 0.78) <0.001
Vitamin D supplementation 0.81 (0.68, 0.96) 0.015
Bisphosphonate therapy 0.59 (0.47, 0.76) <0.001
Serum creatinine >1.5 mg/dl 1.4 (1.1, 1.7) 0.001
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T2DM, type 2
diabetes mellitus; 25OHD, 25hydroxyvitamin D; OR, odds ratio; CI, confidence
interval.
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Several behavioral factors may potentially explain this
association: 1) physicians are more aware of vitamin D
deficiency in older patients; 2) younger patients are
more likely to use sunscreen and/or have a low intake
of vitamin D rich foods, 3) older people are more likely
to take vitamin D and calcium supplementation
[5,31,32]. Alternatively, the association between older
age and vitamin D status may be different in chronic
diseases compared with the general population.
A comparison of vitamin D levels in our patients with the
previously published vitamin D levels from the NHANES
2001 to 2004 data
Although we did not have a general population serving
as a control group, we were able to compare vitamin
D data in our cohort with some of the vitamin D data
reported by Ginde at el in African-American and
Mexican-American men and women stratified by age
in the NHANES 2001 to 2004 [13]. The mean/median
25OHD were comparable in all age groups in African-
American men and women in our cohort and in the
NHANES cohort. The rates of vitamin D <10 ng/ml
were also similar. However, in our cohort the rates of
vitamin D ≥ 30 ng/ml were slightly higher for African-
American men and women over 40 years old com-
pared with the NHANES cohort. 25OHD levels and
the rates of 25OHD <10 ng/ml and ≥ 30 ng/ml were
very different in our Hispanic patients (largely from
Puerto Rico and Dominican Republic) compared with
the Mexican Americans from the NHANES study, sug-
gesting that either the groups were too heterogeneous
or that different factors may be associated with the
vitamin D status in different subpopulations of
Hispanics.
Table 3 25OHD by race/ethnicity
African-American Hispanic Other P-value
SLE, n (column %) 46 39 34
<20 ng/ml 27 (59) 26 (67) 15 (44)
≥20 and <30 ng/ml 16 (35) 9 (23) 11 (32) 0.12
≥30 ng/ml 3 (7) 4 (10) 8 (24)
Median 25OHD (IQR), ng/ml 17.7 (10.0, 24.2) 17.1 (11.3, 23.4) 21.4 (12.0, 28.4) 0.34
RA, n (column %) 32 42 20
<20 ng/ml 15 (47) 21 (50) 6 (30)
≥20 and <30 ng/ml 8 (25) 13 (31) 8 (40) 0.54
≥30 ng/ml 9 (28) 8 (19) 6 (30)
Median 25OHD (IQR), ng/ml 21.5 (14.8, 31.1) 24.7 (20.1, 32.4) 25.3 (17.7, 32.8) 0.28
T2DM, n (column %) 1252 1176 1046
<20 ng/ml 837 (67) 697 (59) 620 (59)
≥20 and <30 ng/ml 249 (20) 308 (26) 280 (27) <0.0001
≥30 ng/ml 166 (13) 171 (15) 146 (14)
Median 25OHD (IQR), ng/ml 15.0 (9.7, 23.1) 17.8 (12.2, 24.7) 17.9 (12.1, 24.3) 0.0001
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T2DM, type 2 diabetes mellitus; 25OHD, 25hydroxyvitamin D; IQR, inter-quartile range.
Table 4 Logistic regression models predicting 25OHD
deficiency in African-Americans, n = 1162
OR (95% CI) P-value
SLE 1.0 -
RA 1.22 (0.45, 3.27) 0.695
T2DM 2.4 (1.2, 4.7) 0.014
Age, for every decade 0.81 (0.74, 0.89) <0.001
Male gender 1.1 (0.79, 1.5) 0.608
October - March season 1.4 (1.1, 1.8) 0.013
Serum calcium, mg/dl 0.76 (0.64, 0.89) 0.001
Vitamin D supplementation 0.84 (0.62, 1.12) 0.23
Bisphosphonate therapy 0.55 (0.33, 1.12) 0.02
Serum creatinine >1.5 mg/dl 1.6 (1.16, 2.2) 0.004
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T2DM, type 2
diabetes mellitus; 25OHD, 25hydroxyvitamin D; OR, odds ratio; C, confidence
interval.
Table 5 Logistic regression models predicting 25OHD
deficiency in Hispanics, n = 1,068
OR (95% CI) P-value
SLE 1.0 -
RA 0.98 (0.37, 2.6) 0.977
T2DM 1.2 (0.59, 2.6) 0.560
Age, for every decade 0.80 (0.73, 0.88) <0.001
Male gender 0.77 (0.56, 1.1) 0.112
October to March season 1.3 (0.98, 1.62) 0.077
Serum calcium, mg/dl 0.66 (0.55, 0.79) <0.001
Vitamin D supplementation 0.92 (0.68, 1.25) 0.613
Bisphosphonate therapy 0.65 (0.44, 0.96) 0.031
Serum creatinine >1.5 mg/dl 1.4 (1.0, 1.97) 0.048
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T2DM, type 2
diabetes mellitus; 25OHD, 25hydroxyvitamin D; OR, odds ratio; CI, confidence
interval.
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Limitations
Our study has several limitations, mainly related to its ret-
rospective nature and the absence of a non-chronic disease
comparison group. In order to evaluate the degree of
selection bias in this retrospective analysis, we compared
patients who had vitamin D measured with patients who
did not have vitamin D measured within each disease cate-
gory. While there were some differences with respect to
the duration of follow-up, age, and laboratory parameters,
these differences were independent of the disease category,
and, therefore, did not significantly bias the odds ratios in
our logistic regression model.
Accurate medication information was sometimes diffi-
cult to obtain retrospectively, and we did not have suffi-
ciently detailed information about sun exposure,
sunscreen use, smoking history, medication compliance,
non-prescription supplementation with vitamin D, nutri-
tional/dietary intake, use of disease modifying medica-
tions, and objective measures of disease severity.
Although we believe this was a non-differential bias,
medication-related information should be interpreted
with caution.
Even though our study showed no association between
prescribed vitamin D supplementation and vitamin D
levels in African-American and Hispanics, there were
both statistically and clinically significant associations
between bisphosphonate therapy and vitamin D status,
suggesting that patients on bisphosphonates were more
likely to be taking vitamin D supplements, either by pre-
scription or non-prescription. Careful assessment of all
medication use, both prescribed and over-the-counter, is
necessary to evaluate the risk of deficiency as well as
total vitamin D intake.
The main objective of this study was to compare the
odds of 25OHD deficiency in SLE, RA, and T2DM. Our
study was not powered sufficiency to look for factors
associated with vitamin D deficiency within each disease
category. Therefore, we did not adjust for disease-speci-
fic factors shown to be associated with 25OHD defi-
ciency in previous studies, such as use of
Hydroxychloroquine (HCQ) in SLE [6,12], corticoster-
oids in SLE and RA [33], or hemoglobin A1c in T2DM
[34]. According to the electronic record, 42 SLE and 6
RA patients were on HCQ at the time when 25OHD
levels were measured, while none of the T2DM patients
were on HCQ. In a subgroup analysis, HCQ was not
significantly associated with 25OHD in our model, and
did not appear to alter our main conclusions.
Although T2DM group was representative of the over-
all T2DM population in our medical center, these
patients may have had more severe T2DM, as all of the
T2DM patients in our study were treated with either
insulin or oral medications for diabetes at the time
when 25OHD was measured. Therefore, the conclusions
reached in our analysis may not be generalizable to
patients with the hemoglobin A1c ≤ 7.0% or patients
with diet controlled T2DM.
Since the disease groups were independent from one
another, inclusion of a disproportionately large T2DM
group did not affect our ability to detect significant dif-
ferences in our sample. Furthermore, when we repeated
bivariate analysis and logistic regression using a random
subsample of 738 (20%) T2DM patients, the main con-
clusions of this analysis did not change significantly.
Albumin measurements were available for only 70% of
patients, and, therefore, we did not adjust our statistical
model for serum albumin or for corrected calcium
values. This could have affected our conclusion that low
serum calcium was associated with vitamin D deficiency.
In addition, 25OHD measurements themselves could be
influenced by low albumin as well, since 10% to 20% of
25OHD is albumin-bound [35]. In a subgroup analysis
of patients who had albumin and serum calcium mea-
sured together, both corrected calcium and albumin
were statistically significant predictors of 25OHD levels.
It will be necessary to address these limitations in
further prospective studies.
Despite the above limitations, the prevalence of vita-
min D deficiency in SLE, RA, and T2DM in our study
was consistent with previous reports in SLE [8], T2DM
[36], and RA [37]. In addition, in our model, the odds of
vitamin D deficiency were associated with African
American race, season with the lower light exposure,
and elevated serum creatinine similar to previous
reports [1]. Therefore, despite the retrospective nature
of this analysis, our data and our conclusions are robust.
Conclusions
Vitamin D deficiency is highly prevalent in the ethnically
diverse patient population with SLE, RA, and T2DM
from a large urban tertiary care center. However, the
Table 6 Logistic regression models predicting 25OHD
deficiency in Others, n = 943
OR (95% CI) P-value
SLE 1.0 -
RA 0.72 (0.18, 2.9) 0.636
T2DM 2.8 (1.3, 6.2) 0.009
Age, for every decade 0.88 (0.79, 0.98) 0.02
Male gender 1.0 (0.74, 1.4) 0.990
October to March season 1.2 (0.89, 1.5) 0.26
Serum calcium, mg/dl 0.64 (0.55, 0.81) <0.001
Vitamin D supplementation 0.67 (0.49, 0.91) 0.012
Bisphosphonate therapy 0.53 (0.34, 0.83) 0.005
Serum creatinine >1.5 mg/dl 1.2 (0.85, 1.7) 0.383
SLE, systemic lupus erythematosus; RA, rheumatoid arthritis; T2DM, type 2
diabetes mellitus; 25OHD, 25hydroxyvitamin D; OR, odds ratio; CI, confidence
interval.
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rates of vitamin D deficiency are not significantly higher
than those reported nationally in the NHANES 2001 to
2004, suggesting that vitamin D deficiency in these
chronic diseases reflects the overall population trends.
Different demographic and laboratory factors are asso-
ciated with 25OHD deficiency within different racial/
ethnic groups. Moreover, the odds of 25OHD deficiency
are different in T2DM compared with SLE and RA.
Therefore, disease specific and race/ethnicity specific
definitions of vitamin D deficiency may need to be
established to determine goals of vitamin D replacement
therapy, and to define outcomes in clinical studies for
vitamin D repletion in autoimmune and non-autoim-
mune chronic diseases.
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